Member Info for Wiggly

I expect we will finish up today. There is is a big buyer

Amazed if we do not finish green.

It's a good time to showcase the data, therefore I suspect rns later today or 7am Monday. Very dangerous to trade this

Madness if so

Concerning professional pride and professional integrity,

DR AS, Dr FM, Dr EF, Dr CM etc will look very silly if Ava6k Data is not truly remarkable

Complete blockbuster if avacta announce all c7 patients have major positive response

Big round trades all day. 5k 10k 25k

"The clinical data emerging for our lead pre|CISIONTM drug, AVA6000, is ground-breaking. We are seeing a dramatic reduction in the usual toxicities associated with anthracycline chemotherapy and we have clear indications that doxorubicin is being released in active form in the tumour microenvironment.

Unbelievable but it's 100% happening

Bye bye 137.

Looks like big stake building in motion.

Really great find.

Based on the snippets of data released I do think further FDA support is a given however, based on historic data, Avacta has an 87% likelihood of receiving Fast track. Breakthrough, accelerated approval or priority review.

So what's the value OF AVA6K when one of these doors is opened by the FDA????

There is HUGE value to big pharma

CJ,

Phase 2 is planned to be a registrational study.

Fyi, Registrational Study means a human clinical trial that is intended (as of the time the clinical trial is initiated) to obtain sufficient data and results to support the filing of an application for Drug Approval of a compound or product.

Following phase 2 completion/approval, Avacta could outsource the production to 3rd party or simply and immediately licence the tech to each Dox player.

I doubt that these options will be reality as buy out will occur prior phase 2 start.

The ability to sell off the Dx wing is an important lever for any ongoing funding negotiations.

We are not desperate and there are avenues enabling avacta to fund AVA6k all the way to final approval / revenue.

Stake building

Beyond the late-stage clinical pipeline, POINT has several additional programs in earlier stages of clinical and preclinical development.

Agree 100%. The time to trade AVCT (If you were) is definitely now over.

Major news.

Point had an exclusive license to 'Ground-Breaking' technology and seems Lilly have acted quickly to secure it. THey will now have sights on the bigger prize (Avacta). I wont be surprised to see other big players move quickly now.

Based on the content of the last RNS, I think its ill advised to compare the market demand now vs the market demand during the last HC conversion.

Avacta confirmed last week that the Pre|CISION platform works! The Chairman has even stated, in a legally approved RNS statement, that the RESULTS are 'Ground-Breaking.'

"The clinical data emerging for our lead pre|CISIONTM drug, AVA6000, is ground-breaking. We are seeing a dramatic reduction in the usual toxicities associated with anthracycline chemotherapy and we have clear indications that doxorubicin is being released in active form in the tumour microenvironment.

Avacta has moved from not wishing to discuss the phase 1a data until completion of the study, to publicly stating that the results are ground-breaking - yet you can still buy today at the same MC as was prior to first patient dose!!!

You can be 100% sure that when Avacta release the detailed data (could be anytime now) it is going to blow the market away. There is no way the Chair makes such a comment in an RNS weeks prior to data release, if said data is not absolutely blockbuster.

I dont think there has ever been such a huge disconnect between market value and asset value.

Neil executed well against his objectives.

JT,

I would also argue that it would be worthwhile to carry out a biopsy of a straight dox (75 mg/m2) patient to directly compare the amount of dox in the tumour between straight dox and ava6k.

Do you think there is chance they will have already done so at MSK under Dr Tap?